Compare Quest Diagnostics Inc (DGX) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs The Coca-Cola Co K — how do they compare? Quest Diagnostics Inc trades at $230.51 (market cap $25.48B), while The Coca-Cola Co K trades at $87.92 (market cap $377.63B). The key difference: The Coca-Cola Co K is far larger — about 14.8× Quest Diagnostics Inc's market cap, and The Coca-Cola Co K pays the higher dividend (2.42%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and The Coca-Cola Co K for 154 Days on average.
| DGX | KO | |
|---|---|---|
Market Cap | $25.48B | $377.63B |
Volume | 941,866 | 14,894,568 |
Sector | Health | Consumer Staples |
52-Week High | $247.45 | $91.99 |
52-Week Low | $173.49 | $66.37 |
Typical Hold Time | 56 Days | 154 Days |
Enterprise Value | $31.23B | $404.81B |
Dividend Yield | 1.49% | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Coca-Cola (KO) trades at $85.82, down 0.41% on the day, with technical indicators showing bearish momentum despite strong fundamentals. The company reported consistent earnings beats in recent quarters with Q2 2026 EPS of $0.97 beating expectations of $0.92. Revenue growth remains steady at $47.94B for 2025, with net income margin improving to 28.56%. Analyst consensus remains bullish with a $95.75 price target, representing 11.6% upside potential from current levels.
The stock presents a compelling dividend opportunity with 64 consecutive years of dividend increases, though technical weakness and regional demand divergence pose near-term risks. Long-term investors may find value in the company's stable cash flows and global brand strength, while short-term traders should monitor support at $85 for potential entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
